Assignee
A2 BIOTHERAPEUTICS INC
US·15 granted patents·16 pending applications·20 citations·filing 2020–2025
Top patents by PatentIndex Score
31 records- 0196US11254726B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2021·Granted Feb 22, 2022·16 cites·16 claims
- 0290US12534509B2Engineered immune cells with receptor cross-talkA2 BIOTHERAPEUTICS INC·Filed 2024·Granted Jan 27, 2026·0 cites·20 claims
- 0390US12195513B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Jan 14, 2025·1 cites·18 claims
- 0490US12187775B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Jan 7, 2025·1 cites·38 claims
- 0589US12459983B2Engineered immune cells with receptor signal strength modulated by a hingeA2 BIOTHERAPEUTICS INC·Filed 2024·Granted Nov 4, 2025·0 cites·10 claims
- 0685US11602544B2Compositions and methods for treating EGFR positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Mar 14, 2023·1 cites·27 claims
- 0782US11433100B2Compositions and methods for treating ceacam positive cancersA2 BIOTHERAPEUTICS INC·Filed 2021·Granted Sep 6, 2022·1 cites·30 claims
- 0879US12595291B2Engineered immune cells with micro-clustersA2 BIOTHERAPEUTICS INC·Filed 2021·Granted Apr 7, 2026·0 cites·16 claims
- 0979US12215134B2Engineered immune cells with dominant signalsA2 BIOTHERAPEUTICS INC·Filed 2021·Granted Feb 4, 2025·0 cites·10 claims
- 1079US12037377B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Jul 16, 2024·0 cites·24 claims
- 1179US12012612B2Engineered immune cells with receptor signal strength modulated by a hingeA2 BIOTHERAPEUTICS INC·Filed 2021·Granted Jun 18, 2024·0 cites·13 claims
- 1279US11976297B2Engineered immune cells with receptor cross-talkA2 BIOTHERAPEUTICS INC·Filed 2021·Granted May 7, 2024·0 cites·20 claims
- 1375US2025145683A1Engineered immune cells with dominant signalsA2 BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1471US2023029341A1Nucleic acid encoding lilrb1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1570US11602543B2Compositions and methods for treating mesothelin positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Mar 14, 2023·0 cites·27 claims
- 1668US2023277590A1Compositions and methods for treating mesothelin positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1767US2024075067A1Compositions and methods for treating her2 positive cancersA2 BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1866US2023277593A1Compositions and methods for treating egfr positive cancersA2 BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1965US12435124B2Compositions and methods for treating CEACAM positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Oct 7, 2025·0 cites·19 claims
- 2065US11730764B2Compositions and methods for treating HER2 positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Aug 22, 2023·0 cites·22 claims
- 2164US2026048125A1Compositions and methods for treating blood cancersA2 BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2260US2025177445A1Engineered receptors specific to hla-e and methods of useA2 BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2359US2024180969A1Polypeptides targeting hla-a*11 and methods of use thereofA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2459US2022370498A1Immune cells expressing receptor specific to class i mhc molecule and interfering rna for hla geneA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2559US2024335471A1Vector systems for delivery of two polynucleotides and methods of making and using sameA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2658US2025269027A1Compositions and methods for treating mesothelin positive cancersA2 BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2757US2022315931A1Immune cells expressing receptor specific to class i mhc molecule and interfering rna for beta2 microglobulin geneA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2854US2024000938A1Adoptive cell therapy for treatment of cancer associated with loss of heterozygosityA2 BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2952US2024173352A1Cell-surface receptors responsive to loss of heterozygosityA2 BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3049US2022389075A1Engineered t cell receptors and uses thereofA2 BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3149US2023257441A1Compositions and methods for treating cancersA2 BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when A2 BIOTHERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →